CAM
TVTX icon

Cresset Asset Management’s Travere Therapeutics TVTX Stock Holding History

Cresset Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$860K Hold
28,933
– – ﹤0.01% 842
2025
Q4 		$1.11M Buy
28,933
+58
+0.2% +$1.89K ﹤0.01% 761
2025
Q3 		$690K Hold
28,875
– – ﹤0.01% 888
2025
Q2 		$427K Buy
28,875
+6,047
+26% +$100K ﹤0.01% 987
2025
Q1 		$409K Buy
22,828
+322
+1% +$6.54K ﹤0.01% 1173
2024
Q4 		$392K Buy
22,506
+131
+0.6% +$2.32K ﹤0.01% 1196
2024
Q3 		$313K Sell
22,375
-186
-0.8% -$1.94K ﹤0.01% 1780
2024
Q2 		$185K Buy
22,561
+4,686
+26% +$31.6K ﹤0.01% 1903
2024
Q1 		$138K Sell
17,875
-108
-0.6% -$911 ﹤0.01% 1816
2023
Q4 		$162K Sell
17,983
-755
-4% -$5.5K ﹤0.01% 1721
2023
Q3 		$168K Buy
18,738
+199
+1% +$2.81K ﹤0.01% 1660
2023
Q2 		$285K Buy
+18,539
New +$337K ﹤0.01% 1551
2022
Q1 		– Sell
-7,139
Closed -$222K – 1147
2021
Q4 		$222K Buy
+7,139
New +$201K ﹤0.01% 1006
2019
Q2 		– Sell
-15
Closed – – 1620
2019
Q1 		$0 Buy
+15
New +$331 ﹤0.01% 2110

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cresset Asset Management's TVTX Position: Q1 2026 in Review

Cresset Asset Management held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 28,933 shares worth $860K. The position accounts for ﹤0.01% of the portfolio, ranked #842.

Cresset Asset Management first reported a position in TVTX in Q1 2019 and has held it in 14 quarters since. The position peaked at $1.11M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Cresset Asset Management held 28,933 shares of Travere Therapeutics worth $860K as of Q1 2026.
  • Cresset Asset Management left its Travere Therapeutics share count unchanged in Q1 2026.
  • Travere Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q1 2026, its #842 holding.
  • Cresset Asset Management first reported a position in Travere Therapeutics in Q1 2019 and has held it in 14 quarters since.
  • Cresset Asset Management's Travere Therapeutics position peaked at $1.11M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.